Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REBUILD-2 galcanezumab in adolescents with chronic migraine
NL-OMON51337Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine comparing Galcanezumab with Placebo (2 arms). Primary endpoint: Overall mean reduction in monthly migraine headache days. Started Sep 2022; status: recruiting.
02
Drugs
galcanezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NL-OMON51337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51337.